NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Generate Biomedicines GENB

Generate Biomedicines listed on Nasdaq on 27 Feb 2026 and is not in the S&P 500. It is worth $1.3 billion. Its price history starts on 27 Feb 2026. 9 directors have filed with the SEC in the last 12 months (who counts), 1 of them an executive. 6 other officers are on file. At 30 Jun 2026, Flagship Pioneering was its largest institutional holder, with 48.9% of the company.

CEO
Michael Nally
Listed
27 Feb 2026 on Nasdaq, IPO filings and terms
Headquarters
Somerville, MA
Market cap
$1.3B
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Financial history

Twelve months to 30 Sep 2026, from Generate Biomedicines's quarterly filings.

Quarters since Mar 2025

P/E
-
No profit over the last four quarters

Quarterly results

Each quarter's revenue, net income and free cash flow.

Mar 2025 to Sep 2026

$0$5M$10M$15M20252026$4M

Generate Biomedicines's market cap since February 2026

Weekly, up to 13 Nov 2026

Mar 2026AprMayJunJulAugSepOctNov$1.6B

Board and leadership

Board and officers

5 people here also hold roles at other S&P 500 companies.

Roles filed up to 30 Sep 2026

NameTitle
Directors (9)
Michael NallyChief Executive OfficerAlso at PPG IndustriesLast filed 6 Mar 2026Chief Executive Officer
Noubar AfeyanDirectorAlso at ModernaLast filed 2 Mar 2026Director
Frances ArnoldDirectorAlso at AlphabetDirector
Stephane BancelDirectorAlso at ModernaLast filed 2 Mar 2026Director
Marsha FanucciDirectorLast filed 2 Mar 2026Director
Jane L. MendilloDirectorLast filed 2 Mar 2026Director
Paul Gray ParkerDirectorLast filed 2 Mar 2026Director
Nancy A. SimonianDirectorLast filed 2 Mar 2026Director
Rupert VesseyDirectorAlso at Bio-TechneLast filed 2 Mar 2026Director
Officers (6)
Jason SilversPresident & CFOLast filed 2 Mar 2026President & CFO
Gevorg GrigoryanChief Technology OfficerLast filed 2 Mar 2026Chief Technology Officer
Beth GrousChief People OfficerLast filed 2 Mar 2026Chief People Officer
Aarif KhakooChief Scientific OfficerLast filed 26 Feb 2026Chief Scientific Officer
Laurie Anne LeeChief Medical OfficerLast filed 2 Mar 2026Chief Medical Officer
Sean MartinChief Legal Officer & GCLast filed 2 Mar 2026Chief Legal Officer & GC

Owners and trading

Largest institutional holders

Each fund group's share of Generate Biomedicines. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

These five hold 60.5% of Generate Biomedicines.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers sold $200,712 of stock in 2 sales and bought $150 million in 5 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
29 Oct 2026SaleFrances ArnoldDirectorDirectorSale11,409$185K
1 Sep 2026SaleFrances ArnoldDirectorDirectorSale1,000$16K
4 Mar 2026BuyMichael NallyChief Executive OfficerChief Executive OfficerBuy20,000$240K
2 Mar 2026BuyNoubar AfeyanDirectorDirectorBuy9,375,000$150M
2 Mar 2026BuyJason SilversPresident & CFOPresident & CFOBuy2,000$32K
2 Mar 2026BuyJane L. MendilloDirectorDirectorBuy1,500$24K
2 Mar 2026BuyBeth GrousChief People OfficerChief People OfficerBuy300$5K

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

1 large insider sale in the last two years.

Left the company or board 0Appointed 0WARN layoff notices 0Large insider sales 1Jan 2025AprJulOctJan 2026AprJulOct

Insider sales of $1 million or more, and the largest tenth of Generate Biomedicines's insider sales.

Events, newest first

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.